T. Morris

发表

Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies

H. Tomkinson, J. Kemp, S. Oliver, 2011, BMC clinical pharmacology.

Quantification of skeletal metastases in castrate‐resistant prostate cancer predicts progression‐free and overall survival

N. Clarke, C. Dive, A. Renehan, 2014, BJU international.

Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer?

P. Iversen, T. Morris, A. Kaisary, 2001, Prostate Cancer and Prostatic Diseases.

Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer

S. Taneja, N. Fleshner, H. Payne, 2008, Prostate Cancer and Prostatic Diseases.

Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration

T. Tammela, P. Iversen, T. Morris, 2006, BJU international.

Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression.

M. Wirth, A. Stone, M. Wallace, 2001, Urology.

Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.

M. Gleave, J. Nelson, J. Moul, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer

M. Wirth, W. See, P. Iversen, 2006, BJU international.

Phase 3, randomized, placebo‐controlled study of zibotentan (ZD4054) in patients with castration‐resistant prostate cancer metastatic to bone

M. Gleave, J. Nelson, J. Moul, 2012, Cancer.

Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC).

M. Gleave, J. Nelson, J. Moul, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer Updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years

T. Tammela, J. Johansson, P. Klarskov, 2006, Scandinavian journal of urology and nephrology.

The influence of nodal status on progression outcomes in patients with prostate cancer: Data from the Early Prostate Cancer program at 7.4 years.

M. Wirth, W. See, P. Iversen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program.

T. Tammela, J. Johansson, J. Montie, 2004, Urology.

Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole

T. Morris, D. Saltzstein, J. Gallo, 2005, Prostate Cancer and Prostatic Diseases.

Prophylactic breast irradiation significantly reduces the incidence of bicalutamide (‘Casodex’)-induced gynecomastia

C. V. D. Beek, H. Payne, S. Andersson, 2002 .

Bicalutamide (‘Casodex’) 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme

M. Wirth, T. Morris, J. Hetherington, 2005, Prostate Cancer and Prostatic Diseases.

Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.

T. Morris, Y. Fradet, J. Armstrong, 2007, European urology.

Phase I study of the specific endothelin A receptor antagonist zibotentan (ZD4054) combined with docetaxel in patients with metastatic castration-resistant prostate cancer: Assessment of efficacy, pain, and safety.

H. Burris, D. Trump, H. Payne, 2010 .

Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration‐resistant prostate cancer

K. Miller, H. Burris, D. Trump, 2011, The Prostate.

In vitro metabolism of the specific endothelin-A receptor antagonist ZD4054 and clinical drug interactions between ZD4054 and rifampicin or itraconazole in healthy male volunteers

S. Oliver, H. Swaisland, M. Taboada, 2009, Xenobiotica; the fate of foreign compounds in biological systems.

A phase III trial of capivasertib and abiraterone versus placebo and abiraterone in patients with de novo metastatic hormone-sensitive prostate cancer characterized by PTEN deficiency (CAPItello-281).

N. Clarke, R. Anjum, D. George, 2021 .

Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow‐up of 9.7 years

M. Wirth, W. See, P. Iversen, 2010, BJU international.

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration‐resistant prostate cancer and bone metastases who were pain‐free or mildly symptomatic for pain: a double‐blind, placebo‐controlled, randomized Phase II tria

N. James, M. Borre, D. Phung, 2010, BJU international.

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.

N. James, M. Borre, D. Phung, 2009, European urology.

A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer.

B. Mellado, R. Hauke, T. Morris, 2021, Clinical genitourinary cancer.

Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer.

K. Haustermans, P. Cangh, H. V. Van Poppel, 2005, European urology.

Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia.

H. Payne, S. Andersson, T. Morris, 2004, International journal of radiation oncology, biology, physics.

Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years.

M. Wirth, W. See, P. Iversen, 2004, The Journal of urology.

881 Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced breast pain and gynaecomastia in prostate cancer

P. Cangh, H. Poppel, T. Morris, 2003 .

Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.

T. Tammela, J. Johansson, O. Lukkarinen, 2004, The Journal of urology.

Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer

M. Gleave, J. Nelson, J. Moul, 2013, Prostate Cancer and Prostatic Diseases.

1238 An open-label study of the pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in subjects with mild, moderate, or severe renal impairment, or normal renal function

H. Tomkinson, S. Oliver, H. Swaisland, 2009 .

Inguinal hernia in stage M0 prostate cancer: a comparison of incidence in men treated with and without radical retropubic prostatectomy--an analysis of 1105 patients.

J. Hugosson, P. Iversen, T. Morris, 2005, Urology.

Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer.

M. Wirth, W. See, P. Iversen, 2003, European urology.

3LB ZD4054, a potent, specific endothelin A receptor antagonist, improves overall survival in pain-free or mildly symptomatic patients with hormone-resistant prostate cancer (HRPC) and bone metastases

N. James, M. Borre, D. Phung, 2007 .

Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.

Tomasz Burzykowski, Laurence Collette, L. Collette, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer

G. Wilding, R. Dreicer, D. Phung, 2011, Investigational New Drugs.

An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers.

H. Tomkinson, J. Kemp, S. Oliver, 2010, Clinical therapeutics.

810: Bicalutamide 150 MG Alone or as Adjuvant to Standard Care Significantly Improves Progression-Free Survival in Patients with Early, Non-Metastatic Prostate Cancer (Median 5.4 Years' Follow-Up)

M. Wirth, W. See, P. Iversen, 2004 .

1062: Bicalutamide 150 mg in Addition to Standard Care Significantly Improves Prostate Specific Antigen Progression-Free Survival in Patients with Early, Non-Metastatic Prostate Cancer: Median 5.4 Years' follow-up

M. Wirth, W. See, P. Iversen, 2004 .

180 Bicalutamide (‘Casodex’) 150 mg in addition to watchful waiting in patients with early non-metastatic prostate cancer: Updated analysis at a median 5.4 years' follow-up

M. Wirth, W. See, P. Iversen, 2004 .

182 Bicalutamide (‘Casodex’) 150 mg as adjuvant to radiotherapy significantly improves progression-free survival in early non-metastatic prostate cancer: Results from the bicalutamide early prostate cancer programme after a median 5.4 years' follow-up

M. Wirth, W. See, P. Iversen, 2004 .

Final results of the STEM trial: SFX-01 in the treatment and evaluation of ER+ Her2- metastatic breast cancer (mBC)

M. Campone, J. Cortes, F. Duhoux, 2019, Annals of Oncology.

A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer.

B. Mellado, R. Hauke, T. Morris, 2022, Clinical genitourinary cancer.

Is prostate-specific antigen progression a surrogate for objective clinical progression in early prostate cancer?

D. Newling, T. Morris, K. Carroll, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.

N. James, M. Borre, D. Phung, 2009, European urology.